Patents by Inventor Christophe Vandier

Christophe Vandier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ion channel inhibitor compounds for cancer treatment
    Patent number: 11932638
    Abstract: The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R? is an -A1-Cy1 group, or R is an -A1-Cy1 group and R? is an R1 group, R1 particularly being H or (C1-C6)alkyl group; A1 being an —NH— radical or —NH—CH2— radical; Cy1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 19, 2024
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE, UNIVERSITE D'ORLEANS, UNIVERSITE DE TOURS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE (INSERM), CHU NANTES
    Inventors: Sylvain Routier, Frédéric Buron, Nuno Rodrigues, Gaëlle Fourriere-Grandclaude, Christophe Vandier, Aurélie Chantome, Marie Potier-Cartereau, Maxime Gueguinou, Séverine Marionneau-Lambot
  • NEW GLYCOLIPIDS AND USE THEREOF AS SK3 ION CHANNEL MODULATORS
    Publication number: 20230287031
    Abstract: New glycolipids derivatives of Formula (I) and their use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels. Also, pharmaceutical compositions including compounds of Formula (I) for use in the treatment of diseases related with a deregulation of the expression and/or activity of SK3 ion channels.
    Type: Application
    Filed: July 16, 2021
    Publication date: September 14, 2023
    Applicants: UNIVERSITÉ DE BRETAGNE OCCIDENTALE, UNIVERSITÉ DE TOURS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Paul Alain JAFFRES, Hélène COUTHON, Charlotte SEVRAIN, Alicia BAUDUIN, Christophe VANDIER, Aurélie CHANTÖME, Delphine FONTAINE
  • ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT
    Publication number: 20210009581
    Abstract: The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R? is an -A1-Cy1 group, or R is an -A1-Cy1 group and R? is an R1 group, R1 particularly being H or (C1-C6)alkyl group; A1 being an —NH— radical or —NH—CH2— radical; Cy1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.
    Type: Application
    Filed: May 23, 2018
    Publication date: January 14, 2021
    Inventors: Sylvain ROUTIER, Frédéric BURON, Nuno RODRIGUES, Gaëlle FOURRIERE-GRANDCLAUDE, Christophe VANDIER, Aurélie CHANTOME, Marie POTIER-CARTEREAU, Maxime GUEGUINOU, Séverine MARIONNEAU-LAMBOT
  • Method for preventing cancer metastasis
    Patent number: 9161944
    Abstract: The present invention relates to the use of a specific family of glycerolipid compounds of formula (I) described in the detailed description or the manufacture of a medicament for the prevention or for the treatment of cancer metastasis.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: October 20, 2015
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE BRETAGNE OCCIDENTALE (U.B.O.), UNIVERSITE FRANCOIS-RABELAIS DE TOURS
    Inventors: Christophe Vandier, Philippe Bougnoux, Aurelle Chantome, Bernard Corbel, Alban Girault, Jean-Pierre Haelters, Virginie Joulin, Marie Potier-Cartereau, Gaelle Simon
  • Method for Preventing Cancer Metastasis
    Publication number: 20130029925
    Abstract: The present invention relates to the use of a specific family of glycerolipid compounds of formula (I) described in the detailed description or the manufacture of a medicament for the prevention or for the treatment of cancer metastasis.
    Type: Application
    Filed: February 17, 2011
    Publication date: January 31, 2013
    Applicants: UNIVERSITE DE BRETAGNE OCCIDENTALE (U.B.O.), INSERM ( INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE FRANCOIS-RABELAIS DE TOURS
    Inventors: Christophe Vandier, Philippe Bougnoux, Aurelie Chantome, Bernard Corbel, Alban Girault, Jean-Pierre Haelters, Virginie Joulin, Marie Potier-Cartereau, Gaelle Simon
  • Method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
    Patent number: 8084196
    Abstract: The present invention relates to methods for the in vitro screening of an anti-metastatic compound that inhibits activity, methods for determining in vitro the presence or absence of a metastatic cancer in a subject by quantifying SK3 activity, methods for the in vitro assessment of the progression of the metastatic property of a cancer by quantifying SK3.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: December 27, 2011
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Marie Potier, Christophe Vandier, Virginie Joulin
  • METHOD FOR THE IN VITRO SCREENING OF ANTI-CANCER COMPOUNDS THAT INHIBITS SK3 ACTIVITY, AND SAID ANTI-CANCER COMPOUNDS
    Publication number: 20090311693
    Abstract: The present invention relates to methods for the in vitro screening of an anti-metastatic compound that inhibits activity, methods for determining in vitro the presence or absence of a metastatic cancer in a subject by quantifying SK3 activity, methods for the in vitro assessment of the progression of the metastatic property of a cancer by quantifying SK3.
    Type: Application
    Filed: August 3, 2007
    Publication date: December 17, 2009
    Applicant: ISERM(Institut National de la Sante et de la Recherche Medicale
    Inventors: Marie Potier, Christophe Vandier, Virginie Joulin